Prognostic Value of p16, Rb, and p53 Proteins in Lung Cancer
Author Information
Author(s): Hommura F, Dosaka-Akita H, Kinoshita I, Mishina T, Hiroumi H, Ogura S, Katoh H, Kawakami Y
Primary Institution: Hokkaido University School of Medicine
Hypothesis
The expression of p16INK4A, retinoblastoma, and p53 proteins can predict the prognosis of non-small-cell lung cancers.
Conclusion
The study found that loss of p16 or Rb proteins does not predict clinical outcomes in patients with resected non-small-cell lung cancers.
Supporting Evidence
- 29% of NSCLCs lacked p16 protein expression.
- 11% of NSCLCs lacked Rb protein expression.
- 39% of NSCLCs showed altered p53 protein expression.
- 5-year survival rates for p16-negative and p16-positive tumours were 67% and 72%, respectively.
- 5-year survival rates for Rb-negative and Rb-positive tumours were 42% and 69%, respectively.
- 5-year survival rates for p16/Rb-negative and p16/Rb-positive tumours were 67% and 68%, respectively.
- 5-year survival rates for p53-positive and p53-negative tumours were 56% and 78%, respectively.
Takeaway
This study looked at how certain proteins in lung cancer cells might help doctors predict how well patients will do, and it found that some proteins don't really help with that.
Methodology
The study evaluated protein expression through immunostaining analyses in patients with potentially curatively resected NSCLCs.
Limitations
The study was limited to a specific cohort of patients and may not generalize to all NSCLC cases.
Participant Demographics
Patients with non-small-cell lung cancers who underwent potentially curative resection.
Statistical Information
P-Value
0.06
Statistical Significance
p=0.06
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website